PeptopiaLab
Sign in
← Back to shop
Retatrutide

RETA · 40 mg / vial

Retatrutide

$300 AUD

Low stock

Triple-agonist research peptide targeting GLP-1, GIP and glucagon receptors.

Purity
≥ 99.3%
Dose
40 mg / vial
Form
Lyophilized
QC
HPLC + MS

What it does

Retatrutide is a next-generation triple agonist that simultaneously activates the GLP-1, GIP and glucagon receptors — the three incretin and energy-balance pathways most central to how the body regulates appetite, insulin and fat storage. In clinical research it has produced some of the largest weight reductions ever recorded for a peptide therapeutic, alongside meaningful improvements in glycaemic control, liver fat and cardiometabolic markers.

How it works in the body

Think of it as flipping three switches at once. Switch one tells your brain you're full, so you eat less. Switch two helps your body use sugar properly, so less of it gets stored as fat. Switch three turns up your body's own furnace, so you burn more energy all day — even the stubborn belly and liver fat.

Researched benefits

  • Significant reductions in body weight and waist circumference in obese trial subjects
  • Lower fasting glucose and HbA1c with reduced hypoglycaemia risk
  • Marked reduction in liver fat (steatosis) and improvement in NAFLD markers
  • Improved blood pressure, triglycerides and LDL cholesterol
  • Sustained appetite suppression and earlier satiety with meals

Typical research protocol

Reconstitution
Add 2 mL bacteriostatic water to the 40 mg vial → 20 mg/mL (1 pen unit = 0.2 mg / 200 mcg).
Dose
Typical research titration: 2 mg → 4 mg → 8 mg → 12 mg weekly, stepping up every 4 weeks as tolerated.
Pen units (U-100)
At 20 mg/mL: 2 mg = 10 units, 4 mg = 20 units, 8 mg = 40 units, 12 mg = 60 units on a U-100 peptide pen.
Frequency
Once weekly, same day each week.

Recommended: use a single-use, sterile drawing syringe and needle for reconstitution — available in the accessories section.

For in-vitro research only — not for human or veterinary consumption.

Potential side effects

  • Nausea, vomiting and reduced appetite — most common, worst in the first days after a dose increase
  • Constipation or diarrhoea, reflux and bloating
  • Fatigue and dizziness, often tied to reduced food and fluid intake
  • Injection-site redness or itching
  • Rapid titration is the main driver of severe GI effects; loss of lean mass reported with aggressive deficits

Reported in published literature and research reports. Not exhaustive and not medical advice — this product is supplied for laboratory research only.

Deep dive · properties

The nerdy details 🔬

Half-life
~6 days (supports once-weekly dosing)
Sequence / class
39-residue synthetic peptide (Eli Lilly LY3437943)
Molecular weight
≈ 4,731 Da
Origin
First-in-human data published 2022 (Coskun et al., Nature Medicine)
Storage & stability
Store lyophilized vials at –20 °C for long-term storage (up to 24 months). Once reconstituted, refrigerate at 2–8 °C and use within 28 days. Protect from light and freeze/thaw cycles.

Common questions

Wait, quick question. 🙋

How does retatrutide compare to tirzepatide or semaglutide?

Semaglutide is a single agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds a third receptor — glucagon — which is what appears to drive the additional fat-loss and hepatic-fat effects observed in phase-2 trials.

Why once weekly?

The molecule is engineered with a fatty-acid side chain that binds albumin, extending its half-life to roughly six days — long enough for a single weekly dose to maintain steady exposure.

What titration schedule is typical in research?

Most published protocols step from 2 mg → 4 mg → 8 mg → 12 mg weekly, moving up every four weeks as GI tolerance allows.

Published research

Where the data lives 📚

Linked purely for research context. Sold for laboratory use only.

Often studied alongside

Pairs well with 💫

Compare peptides side-by-sideReconstitution calculator →

Retatrutide

$300 AUD · 40 mg / vial

Research use only · Not for human or veterinary consumption